conflict(3)/@n_seq/conflict interest(7)-policy(8)/@n_seq/interest-policy researchers(13)/@n_seq/researcher technology(19)/@n_seq/technology ventures(21)/@n_seq/venture financiers(24)/@n_seq/financier researchers(26)/@n_seq/researcher university(28)-administrators(29)/@n_seq/university-administrator ! National(2)-Institutes(3)/@n_seq/National-institute Health(5)-policy(6)/@n_seq/Health-policy researchers(9)/@n_seq/researcher ties(13)/@n_seq/tie health(15)/@n_seq/health care(17)-businesses(18)/@n_seq/care-business government(24)-money(25)/@n_seq/government-money ! concerns(3)/@n_seq/concern agency(6)/@n_seq/agency researchers(8)/@n_seq/researcher business(10)-ties(11)/@n_seq/business-tie findings(17)/@n_seq/finding order(19)/@n_seq/order drugs(23)/@n_seq/drug ! ties(2)/@n_seq/tie academia(4)/@n_seq/academia venture(6)-capital(7)/@n_seq/venture-capital years(12)/@n_seq/year fear(15)/@n_seq/fear abuse(17)/@n_seq/abuse ! guidelines(3)/@n_seq/guideline research(11)/@n_seq/research Kenneth(15)-Smith(16)/@n_seq/Kenneth-Smith provost(19)/@n_seq/provost vice(21)-president(22)/@n_seq/vice-president research(24)/@n_seq/research Massachusetts(26)-Institute(27)/@n_seq/Massachusetts-Institute Technology(29)/@n_seq/Technology ! NIH(2)/@n_seq/NIH grant(5)-recipients(6)/@n_seq/grant-recipient others(8)/@n_seq/others comments(10)/@n_seq/comment guidelines(14)/@n_seq/guideline Dec.(16)/@n_seq/Dec. ! decision(9)/@n_seq/decision policy(12)/@n_seq/policy ! guidelines(2)/@n_seq/guideline future(5)-arrangements(6)/@n_seq/future-arrangement deal(10)/@n_seq/deal Lithox(12)-Inc.(13)/@n_seq/Lithox-Inc. Salem(16)/@n_seq/Salem Mass.(18)/@n_seq/Mass. Robert(25)-Daly(26)/@n_seq/Robert-Daly partner(30)/@n_seq/partner TA(32)-Associates(33)/@n_seq/TA-associate venture(36)/@n_seq/venture capital(38)-firm(39)/@n_seq/capital-firm ! investors(8)/@n_seq/investor Lithox(10)/@n_seq/Lithox year(12)/@n_seq/year gallstone(16)-cure(17)/@n_seq/gallstone-cure researchers(21)/@n_seq/researcher University(24)/@n_seq/University California(26)/@n_seq/California San(28)-Diego(29)/@n_seq/San-Diego ! researchers(2)/@n_seq/researcher Lithox(10)-funds(11)/@n_seq/Lithox-fund royalty(16)/@n_seq/royalty percentage(19)/@n_seq/percentage sales(21)/@n_seq/sale research(25)/@n_seq/research product(29)/@n_seq/product ! University(4)/@n_seq/University California(6)/@n_seq/California universities(11)/@n_seq/university shares(13)/@n_seq/share royalties(15)/@n_seq/royalty researchers(17)/@n_seq/researcher funds(25)/@n_seq/fund guidelines(29)/@n_seq/guideline Mr.(31)-Daly(32)/@n_seq/Mr.-Daly ! tech(4)-industry(5)/@n_seq/tech-industry kind(10)/@n_seq/kind arrangement(12)/@n_seq/arrangement guidelines(16)/@n_seq/guideline ! instance(2)/@n_seq/instance Commonwealth(4)-BioVentures(5)-Inc.(6)/@n_seq/Commonwealth-BioVentures-Inc. venture(9)/@n_seq/venture capital(11)-concern(12)/@n_seq/capital-concern month(15)/@n_seq/month Amira(20)-Inc.(21)/@n_seq/Amira-Inc. Worcester(24)/@n_seq/Worcester Mass.(26)/@n_seq/Mass. concern(28)/@n_seq/concern pharmaceuticals(32)/@n_seq/pharmaceutical ! Scientists(1)-Rima(2)-Kaddurah(3)/@n_seq/scientist-Rima-Kaddurah Daouk(5)/@n_seq/Daouk Paul(7)-Schimmel(8)/@n_seq/Paul-Schimmel research(12)/@n_seq/research Massachusetts(15)-Institute(16)/@n_seq/Massachusetts-Institute Technology(18)/@n_seq/Technology ! Ms.(2)-Kaddurah(3)/@n_seq/Ms.-Kaddurah Daouk(5)/@n_seq/Daouk MIT(7)/@n_seq/MIT Amira(10)/@n_seq/Amira Prof.(12)-Schimmel(13)/@n_seq/Prof.-Schimmel MIT(19)/@n_seq/MIT Amira(23)/@n_seq/Amira board(25)/@n_seq/board equity(30)-stake(31)/@n_seq/equity-stake company(34)/@n_seq/company ! Amira(2)-transaction(3)/@n_seq/Amira-transaction way(8)-venture(9)/@n_seq/way-venture capital(11)-firms(12)/@n_seq/capital-firm task(16)/@n_seq/task biotechnology(19)-research(20)/@n_seq/biotechnology-research ! universities(2)/@n_seq/university research(6)/@n_seq/research venture(9)-capitalists(10)/@n_seq/venture-capitalist ones(13)/@n_seq/one commercialization(19)/@n_seq/commercialization Gloria(23)-W.(24)-Doubleday(25)/@n_seq/Gloria-W.-Doubleday Commonwealth(27)/@n_seq/Commonwealth ! way(6)/@n_seq/way technology(9)/@n_seq/technology campuses(13)/@n_seq/campus ! guidelines(4)/@n_seq/guideline scientists(7)/@n_seq/scientist Prof.(9)-Schimmel(10)/@n_seq/Prof.-Schimmel start(15)/@n_seq/start ups(17)/@n_seq/ups Amira(20)/@n_seq/Amira venture(22)-capitalists(23)/@n_seq/venture-capitalist ! process(8)/@n_seq/process technology(11)/@n_seq/technology marketplace(14)/@n_seq/marketplace ! stakes(2)/@n_seq/stake controversy(5)/@n_seq/controversy ! year(2)/@n_seq/year venture(4)-capitalists(5)/@n_seq/venture-capitalist start(13)/@n_seq/start companies(16)/@n_seq/company biotechnology(20)-businesses(21)/@n_seq/biotechnology-business National(26)-Venture(27)-Capital(28)-Association(29)/@n_seq/National-Venture-Capital-Association trade(32)-group(33)/@n_seq/trade-group ! deals(4)/@n_seq/deal transactions(6)/@n_seq/transaction institutions(10)/@n_seq/institution researchers(12)/@n_seq/researcher work(17)/@n_seq/work return(19)/@n_seq/return equity(22)-stake(23)/@n_seq/equity-stake royalties(25)/@n_seq/royalty ! many(2)/@n_seq/many deals(5)/@n_seq/deal venture(8)-capitalists(9)/@n_seq/venture-capitalist track(13)/@n_seq/track Lawrence(17)-Bock(18)/@n_seq/Lawrence-Bock Avalon(20)-Ventures(21)/@n_seq/Avalon-venture La(23)-Jolla(24)/@n_seq/La-Jolla Calif(26)/@n_seq/Calif ! Investors(1)/@n_seq/investor technologies(8)/@n_seq/technology rights(14)/@n_seq/right technologies(17)/@n_seq/technology ! guidelines(5)/@n_seq/guideline research(10)/@n_seq/research anyone(19)/@n_seq/anyone work(24)/@n_seq/work ! exclusivity(4)/@n_seq/exclusivity venture(7)-capitalists(8)/@n_seq/venture-capitalist incentive(13)/@n_seq/incentive deals(18)/@n_seq/deal Mr.(21)-Bock(22)/@n_seq/Mr.-Bock ! year(2)/@n_seq/year example(5)/@n_seq/example Avalon(7)/@n_seq/Avalon others(9)/@n_seq/others Athena(14)-Neurosciences(15)-Inc.(16)/@n_seq/Athena-neuroscience-Inc. South(18)-San(19)-Francisco(20)/@n_seq/South-San-Francisco Calif.(22)/@n_seq/Calif. technology(28)/@n_seq/technology delivery(30)/@n_seq/delivery drugs(32)/@n_seq/drug brain(35)/@n_seq/brain ! Athena(3)/@n_seq/Athena license(10)/@n_seq/license technology(13)/@n_seq/technology Federal(16)-Register(17)/@n_seq/Federal-Register details(22)/@n_seq/detail company(29)/@n_seq/company competitors(32)/@n_seq/competitor chance(34)/@n_seq/chance Mr.(40)-Bock(41)/@n_seq/Mr.-Bock ! Athena(1)/@n_seq/Athena rights(5)/@n_seq/right technology(8)/@n_seq/technology ! Mr.(4)-Bock(5)/@n_seq/Mr.-Bock close(11)/@n_seq/close ! guidelines(3)/@n_seq/guideline commercialization(7)/@n_seq/commercialization force(11)/@n_seq/force companies(13)/@n_seq/company capital(17)/@n_seq/capital entrepreneurs(19)/@n_seq/entrepreneur ! start(2)/@n_seq/start ups(4)/@n_seq/ups access(9)/@n_seq/access institutions(15)/@n_seq/institution research(28)/@n_seq/research Ruth(32)-Emyanitoff(33)/@n_seq/Ruth-Emyanitoff manager(35)/@n_seq/manager business(37)-development(38)/@n_seq/business-development Applied(40)-bioTechnology(41)-Inc.(42)/@n_seq/Applied-bioTechnology-Inc. Cambridge(45)/@n_seq/Cambridge Mass.(47)/@n_seq/Mass. concern(49)/@n_seq/concern ! research(2)/@n_seq/research time(7)/@n_seq/time start(12)/@n_seq/start Ms.(16)-Emyanitoff(17)/@n_seq/Ms.-Emyanitoff ! part(3)/@n_seq/part NIH(5)/@n_seq/NIH guidelines(9)/@n_seq/guideline research(14)-creativity(15)/@n_seq/research-creativity technology(17)-transfer(18)/@n_seq/technology-transfer research(21)-laboratory(22)/@n_seq/research-laboratory ! Universities(1)/@n_seq/university Harvard(4)/@n_seq/Harvard MIT(6)/@n_seq/MIT way(13)/@n_seq/way brokers(17)/@n_seq/broker scientists(21)/@n_seq/scientist Katherine(24)-Bick(25)/@n_seq/Katherine-Bick NIH(31)-grants(32)/@n_seq/NIH-grant deputy(36)-director(37)/@n_seq/deputy-director research(40)/@n_seq/research ! NIH(1)-staff(2)-members(3)/@n_seq/NIH-staff-member guidelines(6)/@n_seq/guideline escalation(12)/@n_seq/escalation problems(14)/@n_seq/problem ventures(23)/@n_seq/venture ! scientists(5)/@n_seq/scientist stock(7)/@n_seq/stock Spectra(9)-Pharmaceutical(10)-Services(11)-Inc.(12)/@n_seq/spectrum-Pharmaceutical-service-Inc. research(17)/@n_seq/research stock(21)/@n_seq/stock ! officials(2)/@n_seq/official companies(7)/@n_seq/company ride(12)/@n_seq/ride government(15)/@n_seq/government research(18)/@n_seq/research ! subcommitee(3)/@n_seq/subcommitee abuse(9)/@n_seq/abuse researchers(11)/@n_seq/researcher stock(13)/@n_seq/stock companies(15)/@n_seq/company research(18)/@n_seq/research ! provisions(3)/@n_seq/provision NIH(6)-guidelines(7)/@n_seq/NIH-guideline researchers(10)/@n_seq/researcher members(12)/@n_seq/member families(16)/@n_seq/family stock(19)/@n_seq/stock company(22)/@n_seq/company outcome(28)/@n_seq/outcome research(31)/@n_seq/research ! Ms.(1)-Bick(2)/@n_seq/Ms.-Bick NIH(5)-administrator(6)/@n_seq/NIH-administrator business(10)/@n_seq/business community(13)/@n_seq/community agency(19)/@n_seq/agency ideas(25)/@n_seq/idea ! predictions(2)/@n_seq/prediction doom(4)/@n_seq/doom ! agencies(3)/@n_seq/agency NIH(6)/@n_seq/NIH guidelines(8)/@n_seq/guideline policy(15)/@n_seq/policy veteran(17)-scientists(18)/@n_seq/veteran-scientist ! institutions(3)/@n_seq/institution note(7)/@n_seq/note ! Sept.(2)/@n_seq/Sept. Harvard(4)/@n_seq/Harvard conflict(8)/@n_seq/conflict interest(12)-policy(13)-statement(14)/@n_seq/interest-policy-statement effect(18)/@n_seq/effect NIH(23)-guidelines(24)/@n_seq/NIH-guideline ! University(2)/@n_seq/University California(4)/@n_seq/California San(6)-Francisco(7)/@n_seq/San-Francisco memo(12)/@n_seq/memo faculty(16)/@n_seq/faculty contact(20)/@n_seq/contact world(23)/@n_seq/world business(25)/@n_seq/business ! institutions(4)/@n_seq/institution scientists(6)/@n_seq/scientist contacts(9)/@n_seq/contact venture(11)-investors(12)/@n_seq/venture-investor NIH(15)-policy(16)/@n_seq/NIH-policy ! Mr.(2)-Daly(3)/@n_seq/Mr.-Daly venture(6)-capitalist:(7)/@n_seq/venture-capitalist: guidelines(17)/@n_seq/guideline policy(19)/@n_seq/policy ! damage(2)/@n_seq/damage ! 